Yancopoulos
- آذر- 1396 -21 آذردیگر
Development of Eye Disease Combination Therapy Halted by Regeneron, Bayer after Phase II Failures
Regeneron said today it has halted codevelopment with Bayer of a therapy combining the companies’ marketed treatment Eylea® (aflibercept) and Regeneron’s nesvacumab—an up-to-$130 million-plus collaboration…
-- بیشتر بخوانید -- - 2 آذردیگر
Regeneron Genetics Center Surpasses 250K Exomes Sequenced, and Ramping Up
The Regeneron Genetics Center (RGC) has surpassed 250,000 exomes sequenced since its creation three years ago—with a vision of sequencing up to double that number.…
-- بیشتر بخوانید --
